ISSN: 1859 - 2872
The relationship between the value of tumor-infiltrating lymphocytes and pathological complete response in patients with triple-negative breast cancer treated with neoadjuvant therapy
Main Article Content
Keywords
Abstract
Objective: This study aims to evaluate the prognostic value of tumor infiltrating lymphocytes (TILs) for predicting ability of pathologic complete response (pCR). Subject and method: 105 patients with triple-negative breast cancer (TNBC) treated with neoadjuvant therapy at K Hospital. Result: TILs were strongly associated with achieving pCR (OR = 2.41; 95% CI: 1.73 - 3.66). According to receiver operating characteristic (ROC) curve analysis, the AUC was 0.880 for the pembrolizumab group and 0.879 for the chemotherapy group, indicating very good predictive ability of TILs for complete response. With a TILs cut-off of 30%, sensitivity reached 100% in the chemotherapy group, while in the pembrolizumab group, 100% sensitivity was achieved at a TILs cut-off of 50%. Conclusion: These findings suggest that TILs can serve as a predictive biomarker for treatment response in TNBC patients receiving neoadjuvant therapy, in both conventional chemotherapy and immunotherapy combination settings.
Article Details
References
2. Dent R, Hanna WM, Trudeau M et al (2009) Pattern of Relapse and Outcome in Patients with Triple-Negative Breast Cancer (TNBC) According to Type of Adjuvant Chemotherapy. Breast Cancer Res Treat 117(3): 573-582.
3. Cortazar P, Zhang L, Liu S et al (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The US Food and Drug Administration Perspective. JAMA Oncol 1(1): 15-22.
4. Schmid P, Cortes J, Dent R et al (2020) Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 383(26): 2509-2521.
5. Denkert C, Wienke D, Weichert W et al (2015) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. Cancer Res 75(20): 3884-3893.
6. Salgado R, Denkert C, Demaria S et al (2015) The International TILs Working Group 2014: A Report of Standards for the Assessment of TILs in Breast Cancer. Ann Oncol 26(11): 259-271.
7. Mao Y, Zhang S, He Y et al (2016) Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Meta-Analysis of 29 Studies. J Clin Oncol 38(15_suppl): 12569-12569.
8. Amin MB, Edge SB, Greene FL et al (2017) AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
9. Trần Trung Toàn (2004) Lympho bào xâm nhập u và mối liên quan với một số đặc điểm mô bệnh học trong ung thư biểu mô vú bộ ba âm tính. Tạp chí Nghiên cứu Y học 6: 176.
Article Sidebar
